Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Clinical Trial of HG146 Administered to Subjects With Advanced Solid Tumors or Lymphoma

16 september 2026 uppdaterad av: HitGen Inc.

A Phase I Open Label Study of HG146 Alone /in Combination With PD-(L)1 Inhibitor Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors or Lymphoma

This is a Phase I, open-label, repeat-dose, non-randomized, multicenter study to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of HG146 administered orally (PO) alone (Part 1) or co-administered (Part 2) with PD-(L)1 inhibitor in subjects with refractory/relapsed solid tumors or Lymphoma. Part 1 consists of a dose escalation phae,Part2 consists of a dose escalation phase and a cohort expansion phase. In Part 1, escalating doses of HG146 will be evaluated as guided by the "3+3" approach. In Part 2A, escalating doses of HG146 in combination with PD-(L)1 inhibitor will be evaluated as guided by the "3+3" approach. In Part 2B, subjects will receive a single dose level of HG146 as identified based on data from Part 2, in combination with PD-(L)1 inhibitor . A total of approximately 96 subjects will be enrolled in this study, approximately 36 for dose escalation cohorts, and approximately 60 in the expansion cohorts.

Studieöversikt

Status

Avslutad

Betingelser

Studietyp

Interventionell

Inskrivning (Faktisk)

24

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Beijing, Kina
        • National Cancer Center/Cancer Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Key Inclusion Criteria:

1 Subject must be >=18 years of age at the time of signing the informed consent.

2- Ia/Ib dose escalation phase(Part1 and Part 2A):Subjects with advanced/Metastatic solid tumors or Lymphoma, who have progressed on, be intolerant of, or ineligible for, all available therapies for which clinical benefit has been established.

  • Ib dose expansion phase(Part 2):

    1. Cohort 1,Subjects with advanced/Metastatic solid tumors or Lymphoma, who have progressed on, be intolerant of, or ineligible for, all available therapies for which clinical benefit has been established, have not been treated with PD-(L)1 antibody; 2)Cohort 2,Subjects with advanced/Metastatic solid tumors or Lymphoma, who have progressed on, be intolerant of, or ineligible for, all available therapies for which clinical benefit has been established, have progressed on PD-(L)1 antibody; 3 Measurable disease per RECIST version 1.1 or Lugano 2014(If applicable). 4 Has Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1. 5 Has adequate organ function. 6 Signed informed consent form (ICF) and able to comply with study requirements.

Key Exclusion Criteria:

  1. Received prior therapies targeting HDAC.
  2. Symptomatic central nervous system (CNS) metastases that have required steroids within 4 weeks prior to first dose of study treatment.
  3. History of intolerant of anti-PD-(L)1 toxicity(Ib).
  4. A condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of enrollment.
  5. Major surgery or major injury <=28 days before the first dose of study treatment,or anticipated major surgery during the study.
  6. Received other anticaner therapies within 4 weeks prior to first dose of study treatment or 5 half life period of anticancer drug .
  7. Active infection requiring systemic treatment.
  8. Prior allogeneic bone marrow transplantation or other solid organ transplantation ( Ib)
  9. Active autoimmune disease or disease of impaired immune system(Ib).
  10. History of Adrenal insufficiency.(Ib)
  11. History orConcurrent condition of other malignant tumors.
  12. Recent (within the past 6 months) history of Unstable or serious diseases, such as pancreatitis, severe angina, prolonged QT interval, congestive heart failure, myocardial infarction, pulmonary hypertension, stroke, and severe seizures, etc.
  13. History of severe lung disease.
  14. Any illness or medical conditions that are unstable or could jeopardize the safety of the patient and his/her compliance in the study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Part 1:HG146 Monotherapy, Dose-escalation Cohort

Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, 21 days/ cycle. Escalating doses of HG146 will be evaluated using 3+3 approach.

HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.

Andra namn:
  • HG146 capsule
Experimentell: Part 2A:HG146 + PD-(L)1 antibody, Dose escalation Cohort

Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, along with PD-(L)1 antibody IV once every 3 weeks (Q3W),21 days/ cycle.

Escalating doses of HG146 in combination with PD-(L)1 antibody will be evaluated.

HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.

Andra namn:
  • HG146 capsule

PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.

Andra namn:
  • PD-1 antikropp
Experimentell: Part 2B-1:HG146 combination Expansion Cohort 1

Subjects who have not been treated with PD-(L)1 antibody,will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.

HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.

Andra namn:
  • HG146 capsule

PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.

Andra namn:
  • PD-1 antikropp
Experimentell: Part 2B-2:HG146 combination Expansion Cohort 2

Subjects who have progressed on PD-(L)1 antibody, will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.

HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.

Andra namn:
  • HG146 capsule

PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.

Andra namn:
  • PD-1 antikropp

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Part I:Dose-Limiting Toxicities (DLTs)
Tidsram: Up to 26 Days in Cycle 0 and Cycle 1

Number of participants experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE V5.0)

Up to 26 Days in Cycle 0 and Cycle 1
Part I:Serious Adverse Events (SAEs) and Adverse Events (AE)
Tidsram: Up to 2 years

Number of participants experiencing Serious Adverse Events (SAEs) and Adverse Events (AE) According to Safety performance.

Up to 2 years
Part I:Maximum tolerated dose or Recommended Phase Ib dose (RP2D) of HG146
Tidsram: Up to 2 years

Maximum tolerated dose or Recommended Phase II dose of HG146 will be decided according to safety and effective results.

Up to 2 years
Part 2A: Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v.5.0)
Tidsram: Up to 21 Days in Cycle 1

Number of participants experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE V5.0)

Up to 21 Days in Cycle 1
Part 2A: Serious Adverse Events (SAEs) and Adverse Events (AE)
Tidsram: Up to 2 years

Number of participants experiencing Serious Adverse Events (SAEs) and Adverse Events (AE) According to Safety performance.

Up to 2 years
Part 2A:Maximum tolerated dose or Recommended Phase II dose (RP2D) of HG146 in combination with PD-(L)1 antibody
Tidsram: Up to 2 years

Maximum tolerated dose or Recommended Phase II dose of HG146 will be decided according to safety and effective results.

Up to 2 years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Part 1:Area under the concentration versus time curve (AUC) of HG146
Tidsram: At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)

Plasma concentration of HG146 will be measured following single dose and multiple dose administration

At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)
Part 1:Peak plasma concentration (Cmax) of HG146
Tidsram: At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)

Plasma concentration of HG146 will be measured following single dose and multiple dose administration

At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)
Part 1:Time of Cmax (Tmax) of HG146
Tidsram: At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15(Except for cycle 0, each cycle is 21 days)

Plasma concentration of HG146 will be measured following single dose and multiple dose administration

At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15(Except for cycle 0, each cycle is 21 days)
Part 1:Apparent terminal half-life (T1/2) of HG146
Tidsram: At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)

Plasma concentration of HG146 will be measured following single dose and multiple dose administration

At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)
Part1: objective response rate (ORR)
Tidsram: Up to 2 years

ORR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

Up to 2 years
Part1: Best overall response (BOR)
Tidsram: Up to 2 years

BOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

Up to 2 years
Part1: Duration of response (DOR)
Tidsram: Up to 2 years

DOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

Up to 2 years
Part 1:Time-to-response (TTR)
Tidsram: Up to 2 years

TTR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

Up to 2 years
Part 1:Progression-Free Survival (PFS)
Tidsram: Up to 2 years

PFS will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

Up to 2 years
Part 2:Area under the concentration versus time curve (AUC) of HG146
Tidsram: At the end of Cycle 1 Day 15 (each cycle is 21 days)

Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody

At the end of Cycle 1 Day 15 (each cycle is 21 days)
Part 2:maximum observed plasma concentration (Cmax) of HG146
Tidsram: At the end of Cycle 1 Day 15 (each cycle is 21 days)

Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody

At the end of Cycle 1 Day 15 (each cycle is 21 days)
Part 2:time of maximum observed plasma concentration (Tmax) of HG146
Tidsram: At the end of Cycle 1 Day 15 (each cycle is 21 days)

Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody

At the end of Cycle 1 Day 15 (each cycle is 21 days)
Part 2:apparent terminal half-life (T1/2) of HG146
Tidsram: At the end of Cycle 1 Day 15 (each cycle is 21 days)

Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody

At the end of Cycle 1 Day 15 (each cycle is 21 days)
Part2: objective response rate (ORR)
Tidsram: Up to 2 years

ORR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

Up to 2 years
Part2: Best overall response (BOR)
Tidsram: Up to 2 years

BOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

Up to 2 years
Part2: Duration of response (DOR)
Tidsram: Up to 2 years

DOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

Up to 2 years
Part 2:Time-to-response (TTR)
Tidsram: Up to 2 years

TTR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

Up to 2 years
Part 2:Progression-Free Survival (PFS)
Tidsram: Up to 2 years

PFS will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

Up to 2 years
Overall survival (OS)
Tidsram: Up to 2 years

OS will be assessed by the investigators

Up to 2 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Huvudutredare: Yuankai Shi, National Cancer Center/Cancer Hospital

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 september 2021

Primärt slutförande (Faktisk)

13 juni 2024

Avslutad studie (Faktisk)

22 december 2024

Studieregistreringsdatum

Först inskickad

12 juli 2021

Först inskickad som uppfyllde QC-kriterierna

23 juli 2021

Första postat (Faktisk)

26 juli 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

21 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera